|
Veloxis’ Phase 3 Trial of LCP-Tacro in Stable Kidney Transplant Patients, the …
FierceDrugDelivery Non-inferiority was determined by a composite endpoint, measured over a year of follow up that included death, graft failure, biopsy-proven acute rejection or loss to follow-up. Results of this trial demonstrated that patients can be successfully … |
|
Mass. Eye and Ear ophthalmologist receives Senior Scientific Investigator Award
Phys.Org (press release) “I am delighted to have received this support from RPB, which will aid us tremendously in our investigations of ocular surface inflammation in eyes deemed at high risk of corneal transplant rejection,” said Dr. Dana. “With this support, we will be able … |
|
IncellDx Presents First Study Using Their Novel OncoBreast 3Dx‚Ñ¢ Breast …
PharmiWeb.com (press release) About IncellDx, Inc. IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis, and organ transplant rejection. For more … |
|
IncellDx Presents First Study Using Their Novel OncoBreast 3Dx™ Breast …
The Herald | HeraldOnline.com … 3Dx platform,” he added. About IncellDx, Inc. IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis, and organ transplant … |
FDA grants orphan label to eye cancer chemo-delivery comboFierceDrugDeliveryThe company also uses the delivery system in treatments for inflammation associated with cataract surgery, cystoid macular edema, glaucoma, macular degeneration, uveitis and co…
Medistem Inc. Annual Letter to ShareholdersMelodika.net (press release)Also, in collaboration with several corporate and academic institutions we published a total of 7 peer reviewed papers in 2012 on collaborative breakthroughs we made in the areas of…
|
Orgenesis Announces Management Changes
Virtual-Strategy Magazine (press release) The Company believes that converting the diabetic patient’s own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transplant rejection. If successful, this could mean the end of diabetes, as we now know it. |
|
Orgenesis Announces Management Changes
MarketWatch (press release) The Company believes that converting the diabetic patient’s own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transplant rejection. If successful, this could mean the end of diabetes, as we now know it. |
 The Inquisitr |
The Cure For Cancer And HIV May Be On The Way
The Inquisitr The best part is the technique only boosts the power of the immune system, so the chances of transplant rejection are small. Two experiments were conducted – one targeting skin cancer and the other targeting HIV, says the BBC. The team used T-cells … Have Japanese Researchers Invented the Cure for Cancer and HIV?Medical Daily |
|
Mass. Eye and Ear/Harvard Medical School Ophthalmologist Receives …
Newswise (press release) “I am delighted to have received this support from RPB, which will aid us tremendously in our investigations of ocular surface inflammation in eyes deemed at high risk of corneal transplant rejection,” said Dr. Dana. “With this support, we will be able … |